EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS acquired by PERKINELMER

Permira, the global private equity firm, acquired a majority stake in Corin Group, a UK-based leader in orthopaedic innovation, from a consortium of investors including DeA Capital, Hunt Capital, and IP (Investimenti e Partecipazioni). Permira's thesis was centered on accelerating Corin's international scale—particularly in the US and Australian markets—and fueling an aggressive buy-and-build strategy to integrate digital health and robotic capabilities into the core implant business. This approach aimed to position Corin as a "Challenger OEM" capable of disrupting larger incumbents through superior product innovation and data-driven patient monitoring

The integration of Paragon Medical into the NN, Inc. life sciences portfolio represents a definitive shift in the group's overarching corporate strategy. By absorbing Paragon Medical, NN, Inc. significantly enhances its technical proficiencies and diversifies its finished device offerings, moving beyond traditional industrial components into highly regulated healthcare markets. The strategic rationale for the transaction centers on the fusion of Paragon Medical’s niche leadership in orthopedic instrumentation with NN, Inc

CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.

Théradial has completed a shareholder restructuring agreement, welcoming UI Gestion and Bpifrance as new majority shareholders. This transaction is part of a management buy-out, enabling Frédéric Le Pottier, the former Commercial Director, to take the helm as Chairman of the Executive Board. Meanwhile, Bruno Duval, the company's founder, will retain a key role as a shareholder and become Chairman of the Supervisory Board. The goal of this transaction is to support Théradial's growth strategy, which aims to leverage its pharmaceutical establishment status, obtained two years ago, to expand its product portfolio

Fresenius Medical Care announced a definitive agreement to acquire all outstanding shares of NxStage Medical. The acquisition is strategically central to FMC's 2020 strategic initiative, positioning the combined entity as a global leader in home dialysis by integrating NxStage's System One platform into FMC's vertically integrated dialysis ecosystem. The transaction is expected to generate net cost synergies of approximately $80–100 million per annum before tax over three to five years, with integration costs of approximately $150 million over the first three years

EQT VII has entered into an agreement to acquire a 20% minority stake in Ottobock, as part of a strategic partnership aimed at supporting Ottobock's international growth ambitions, driving its strategic objectives, and potentially preparing the company for a future initial public offering (IPO) in the medium term. The investment by EQT comes at a time of significant transformation in the mobility technology market, driven by an aging population, increasing demand for rehabilitation solutions, and advancements in smart prosthetics

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership

Orchestrating a major shift in the European medtech landscape, this majority buyout extracts ELITechGroup from its previous financial framework to catalyze an aggressive international scaling phase. The strategic rationale centers on leveraging the target's specialized molecular diagnostic footprint to navigate the maturing global healthcare sector. Rather than a simple portfolio addition, this move represents a calculated bet on the structural transition toward decentralized laboratory automation and precision pathology

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting

The acquisition of Vention Advanced Technologies by Nordson Corporation signifies a major step in the group’s expansion into the high-growth medtech sector. The strategic logic of this transaction hinges on a "market-balancing" maneuver, merging the target’s industry-leading technical operational depth in interventional delivery systems with the buyer’s established scale in precision fluid management. This alignment equips the combined organization with the scientific talent and manufacturing hardware necessary to address the increasing demand for minimally invasive medical solutions across North America, Europe, and Asia